The microtip partnership assay (MPA) program helps Ortho in validating and in offering high value, esoteric testing, in step with the evolving needs of today’s labs.

The assays Glycated Serum Protein (GSP), Lipoprotein (a) (Lp (a)), and Cystatin C allow the company to expand its offerings in diabetes, cardiac and renal areas.

The GSP assay enriches and expands Ortho’s diabetes menu offering and adds to its recent launches of Insulin, C-Peptide and Beta-Hydroxybutyrate (MPA).

Glycemic monitoring is considered to be critical in preventing or delaying diabetes related complications and co-morbidities.

Lp (a) helps expand Ortho’s offering of diagnostic cardiac markers as one of the important tests for patients who may carry a genetic risk factor for premature cardiovascular disease including risk-stratification for myocardial infarction and stroke.

Cystatin C is a key marker in early diagnosis for kidney disease and complements serum creatinine testing.

Ortho Clinical says that by combining Cystatin C with serum creatinine, one can improve the predictive accuracy for all-cause mortality and end-stage renal disease as it is a sensitive marker in the ‘creatinine blind range’ in kidney testing.

Thes assays will be launched in the US, Europe, Africa and the Middle East.

Ortho chief operating officer Robert Yates said: “Our MicroTip Partnership Assay program helps us expand our reach in delivering innovative, important new assays to our customers. Ortho is a leader in testing in diabetes, cardiac and renal areas, and the three new assays we announce today further that position and commitment.”

Headquartered in New Jersey, Ortho Clinical Diagnostics offers in vitro diagnostics services. The company’s products and services are available in more than 125 countries and territories.

The company offers testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care.